HomeCompareASAPF vs HTGC

ASAPF vs HTGC: Dividend Comparison 2026

ASAPF yields 966.18% · HTGC yields 12.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ASAPF wins by $13971086.90M in total portfolio value
10 years
ASAPF
ASAPF
● Live price
966.18%
Share price
$0.21
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$13971087.62M
Annual income
$11,607,748,173,159.94
Full ASAPF calculator →
HTGC
Hercules Capital Inc.
● Live price
12.73%
Share price
$14.77
Annual div
$1.88
5Y div CAGR
32.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$718.3K
Annual income
$326,530.50
Full HTGC calculator →

Portfolio growth — ASAPF vs HTGC

📍 ASAPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodASAPFHTGC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ASAPF + HTGC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ASAPF pays
HTGC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASAPF
Annual income on $10K today (after 15% tax)
$82,125.60/yr
After 10yr DRIP, annual income (after tax)
$9,866,585,947,185.95/yr
HTGC
Annual income on $10K today (after 15% tax)
$1,081.92/yr
After 10yr DRIP, annual income (after tax)
$277,550.93/yr
At 15% tax rate, ASAPF beats the other by $9,866,585,669,635.02/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASAPF + HTGC for your $10,000?

ASAPF: 50%HTGC: 50%
100% HTGC50/50100% ASAPF
Portfolio after 10yr
$6985544.17M
Annual income
$5,803,874,249,845.22/yr
Blended yield
83.08%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on HTGC right now

ASAPF
No analyst data
Altman Z
-0.6
Piotroski
3/9
HTGC
Analyst Ratings
17
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$18.81
+27.4% upside vs current
Range: $17.50 — $19.75
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASAPF buys
0
HTGC buys
0
No recent congressional trades found for ASAPF or HTGC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricASAPFHTGC
Forward yield966.18%12.73%
Annual dividend / share$2.00$1.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.5%
Portfolio after 10y$13971087.62M$718.3K
Annual income after 10y$11,607,748,173,159.94$326,530.50
Total dividends collected$13789621.78M$623.4K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: ASAPF vs HTGC ($10,000, DRIP)

YearASAPF PortfolioASAPF Income/yrHTGC PortfolioHTGC Income/yrGap
1← crossover$107,318$96,618.36$12,667$1,686.53+$94.7KASAPF
2$1,083,889$969,058.26$16,486$2,577.89+$1.07MASAPF
3$10,306,723$9,146,961.82$22,150$4,048.82+$10.28MASAPF
4$92,316,658$81,288,464.37$30,886$6,564.64+$92.29MASAPF
5$779,241,977$680,463,152.91$44,958$11,045.93+$779.20MASAPF
6$6,201,796,258$5,368,007,343.00$68,767$19,403.05+$6201.73MASAPF
7$46,563,639,005$39,927,717,008.65$111,321$35,814.23+$46563.53MASAPF
8$329,992,119,548$280,169,025,812.28$192,192$69,962.21+$329991.93MASAPF
9$2,208,728,456,915$1,855,636,888,999.35$356,787$145,759.66+$2208728.10MASAPF
10$13,971,087,622,059$11,607,748,173,159.94$718,282$326,530.50+$13971086.90MASAPF

ASAPF vs HTGC: Complete Analysis 2026

ASAPFStock

Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada. The company offers interspinous process lumbar fusion devices, such as the ZIP, ZIP ULTRA, ZIP LP, and ZIP-51 for patients suffering from degenerative disc diseases; and Ti-Coated polyether ether ketone interbody cages, which provide spacing and stability between the vertebrae while bone grows to complete the fusion process. It also provides sterile-packed titanium plasma spray coated spinal infusion implants for bone growth, as well as interbody products, such as EOS, VOX, Echo, Echo SD, and EchoXL for the lumbar section of the spine, and discovery for cervical procedures. In addition, the company provides SOLO, an anterior lumbar interbody fusion 3D printed stand-alone fusion device, which is an integrated plate and spacer system that helps to preserve the natural anatomic profile while providing spinal column support and stability; and SiLo, a posterior fusion device for the sacroiliac joint. Further, it offers DEXA-C, a cervical interbody system, which is a porous 3D-printed intervertebral body fusion device that incorporates low-, mid-, or high-density lattice pattern options to support the matching of patients' bone quality. Aurora Spine Corporation was incorporated in 2013 and is headquartered in Toronto, Canada.

Full ASAPF Calculator →

HTGCBDC

Hercules Capital, Inc. is a business development company. The firm specializing in providing venture debt, debt, senior secured loans, and growth capital to privately held venture capital-backed companies at all stages of development from startups, to expansion stage including select publicly listed companies and select special opportunity lower middle market companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing solutions; company, asset specific, or intellectual property acquisition financing; convertible, subordinated and/or mezzanine loans; domestic and international corporate expansion; vendor financing; revenue acceleration by sales and marketing development, and manufacturing expansion. It provides asset-based financing with a focus on cash flow; accounts receivable facilities; equipment loans or leases; equipment acquisition; facilities build-out and/or expansion; working capital revolving lines of credit; inventory. The firm also provides bridge financing to IPO or mergers and acquisitions or technology acquisition; dividend recapitalizations and other sources of investor liquidity; cash flow financing to protect against share price volatility; competitor acquisition; pre-IPO financing for extra cash on the balance sheet; public company financing to continue asset growth and production capacity; short-term bridge financing; and strategic and intellectual property acquisition financings. It also focuses on customized financing solutions, emerging growth, mid venture, and late venture financing. The firm invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The firm generally seeks to invest in companies that have been operating for at least six to 12 months prior to the date of their investment. It prefers to invest in technology, energy technology, sustainable and renewable technology, and life sciences. Within technology the firm focuses on advanced specialty materials and chemicals; communication and networking, consumer and business products; consumer products and services, digital media and consumer internet; electronics and computer hardware; enterprise software and services; gaming; healthcare services; information services; business services; media, content and information; mobile; resource management; security software; semiconductors; semiconductors and hardware; and software sector. Within energy technology, it invests in agriculture; clean technology; energy and renewable technology, fuels and power technology; geothermal; smart grid and energy efficiency and monitoring technologies; solar; and wind. Within life sciences, the firm invests in biopharmaceuticals; biotechnology tools; diagnostics; drug discovery, development and delivery; medical devices and equipment; surgical devices; therapeutics; pharma services; and specialty pharmaceuticals. It also invests in educational services. The firm invests primarily in United States based companies and considers investment in the West Coast, Mid-Atlantic regions, Southeast and Midwest; particularly in the areas of software, biotech and information services. The firm prefers to invest between $10 million to $250 million in equity per transactions. It invests generally between $1 million to $40 million in companies focused primarily on business services, communications, electronics, hardware, and healthcare services. The firm invests primarily in private companies but also have investments in public companies. For equity investments, the firm seeks to represent a controlling interest in its portfolio companies which may exceed 25% of the voting securities of such companies. The firm seeks to invest a limited portion of its assets in equipment-based loans to early-stage prospective portfolio companies. These loans are generally for amounts up to $3 million but may be up to $15 million for certain energy technology venture investments. The firm allows certain debt investments have the right to convert a portion of the debt investment into equity. It also co-invests with other private equity firms. The firm seeks to exit its investments through initial public offering, a private sale of equity interest to a third party, a merger or an acquisition of the company or a purchase of the equity position by the company or one of its stockholders. The firm has structured debt with warrants which typically have maturities of between two and seven years with an average of three years; senior debt with an investment horizon of less than three years; equipment loans with an investment horizon ranging from three to four years; and equity related securities with an investment horizon ranging from three to seven years. The firm prefers to invest through its balance sheet capital. The firm formerly known as Hercules Technology Growth Capital, Inc. Hercules Capital, Inc. was founded in December 2003 and is based in Palo Alto, California with additional offices in Connecticut; Boston, Massachusetts; San Diego, California; Westport, Connecticut; Elmhurst, Illinois; Santa Monica, California; McLean, Virginia; New York, New York; Radnor, Pennsylvania; and Washington, District of Columbia and London, United Kingdom.

Full HTGC Calculator →
📬

Get this ASAPF vs HTGC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASAPF vs SCHDASAPF vs JEPIASAPF vs OASAPF vs KOASAPF vs MAINASAPF vs ARCCASAPF vs GBDCASAPF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.